Literature DB >> 7386234

The antihypertensive effect of prazosin on mild to moderate hypertension, changes in plasma volume, extracellular volume and glomerular filtration rate.

A McNair, S Rasmussen, P E Nielsen, K Rasmussen.   

Abstract

Changes in blood pressure, plasma volume (PV) (125I-albumin space), extracellular volume (ECV) (82Br-space) and glomerular filtration rate (GFR) (51Cr-EDTA clearance) were measured in 12 patients with mild to moderate essential hypertension on placebo and during long-term treatment with prazosin. During the study, BP decreased from an average of 172/107 to 166/102 mmHg (n.s.). PV increased from 3278 to 3324 ml (n.s.) and ECV from 18360 to 18639 ml (n.s.). GFR was almost unchanged, 95 and 93 ml/min, prespectively. An inverse significant correlation was found between the changes in mean BP and changes in ECV, i.e. fluid retention was demonstrated in patients with the smallest BP reduction. It is concluded that inadequate BP response during treatment with prazosin may in part be due to fluid retention. It is therefor suggested that prazosin should in principle be used together with a diuretic in order to prevent fluid retention.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7386234     DOI: 10.1111/j.0954-6820.1980.tb09748.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  6 in total

Review 1.  Influence of antihypertensive therapy on renal function.

Authors:  U Frei; R Schindler; K M Koch
Journal:  Clin Investig       Date:  1992

2.  Treatment of essential hypertension with felodipine in combination with a diuretic.

Authors:  T Hedner; O Samuelsson; E Sjögren; D Elmfeldt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Heart failure in hypertension: prevention and treatment.

Authors:  Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos; Javed Butler
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

4.  Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension.

Authors:  D Elmfeldt; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.

Authors:  D Torvik; H P Madsbu
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 6.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.